Progenra
  • About
    • Investor Relations
    • Leadership
  • Therapeutic Focus
    • The Ubiquitin Proteasome System (UPS)
    • UbiPro™ Platform
    • PROTAC Platform
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog
Select Page

Progenra discusses role of small molecules and USP7 in immune oncology on Cambridge Healthtech Institue podcast

by admin | Sep 27, 2017 | News

Recently, Dr. Tauseef Butt, President and CEO, spoke with Joel Hornby of Cambridge Healthtech Institute. Dr. Butt spoke of the role that small molecules, specifically inhibitors of ubiquitin protease 7 (USP7), play in immune oncology. In addition, Dr. Butt discussed...

Recent Posts

  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
  • Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch
  • Protein Misfolding-Neurodegeneration
  • Ubiquitination and Cancer

Archives

  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015
Progenra Logo

Contact

  610.644.6974
  610.644.8616
   277 Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2019 Progenra Inc. All Rights Reserved.
Website Designed by eNet Web Services